Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | FGF2 | P09038 | 1/20 | 0.53 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | POLA1 | P09884 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10237705 | 0.91 | CYP46A1 (0.63) | CYP1A2CYP46A1NR1H3NPC1POLA1 | |
| SCHEMBL25747241 | 0.91 | CYP46A1 (0.63) | CYP1A2CYP46A1NR1H3NPC1POLA1 | |
| SCHEMBL16476477 | 0.91 | CYP1A2 (0.58) | CYP1A2FGF2CYP46A1NR1H3NPC1 | |
| SCHEMBL20828510 | 0.85 | CYP1A2 (0.57) | CYP1A2FGF2CYP46A1NR1H3NPC1 | |
| SCHEMBL25797981 | 0.84 | CYP46A1 (0.62) | CYP1A2CYP46A1NR1H3NPC1POLA1 | |
| SCHEMBL17212337 | 0.82 | CYP46A1 (0.59) | CYP1A2FGF2CYP46A1NR1H3NPC1 | |
| SCHEMBL18622135 | 0.82 | CYP46A1 (0.59) | CYP1A2FGF2CYP46A1NR1H3NPC1 | |
| SCHEMBL19566728 | 0.81 | CYP46A1 (0.67) | CYP1A2FGF2CYP46A1NR1H3NPC1 | |
| SCHEMBL16476474 | 0.81 | CYP46A1 (0.67) | CYP1A2FGF2CYP46A1NR1H3NPC1 | |
| SCHEMBL17212338 | 0.81 | POLA1 (0.54) | CYP46A1NR1H3NPC1POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629101-B2 | Cholesterol derivatives of inhibitors of viral fusion | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2014-01-14 | — | — | US | disclosed |
| US-20100305028-A1 | CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION | MSD ITALIA S.R.L. (IT) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305028-A1 | CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION | HDLBP, CETP, NPC1 | CYP1A2 3237/4885FGF2 1032/4885CYP46A1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.